By the Top Tier Newswire AI Desk · reviewed against 11 wire stories
ANNEXON INC (ANNX) is drawing unusual attention today. Our newswire has captured 11 stories on ANNX across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for ANNX publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
AI sentiment, last 36h · averaged over 11 stories · 54/100 neutral
The headlines behind the move
Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoSeeking AlphaBULLISH 63Product/PR
Annexon outlines Q4 BLA filing for tanruprubart while adding month 24 dual primary endpoint to ARCHER II
Annexon (ANNX) Q2 2026 earnings call: ARCHER II Phase III expansion, month-15 Q4 readout, BLA timeline, and $200M runway—read insights now.
5h agoSeeking AlphaNEUTRAL 50Earnings
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon, Inc. (ANNX) Q2 2026 Earnings Call August 12, 2026 8:00 AM EDTCompany ParticipantsDouglas Love - CEO, President & DirectorJamie Dananberg -...
10h agoYahoo TopBULLISH 63Product/PR
Annexon Q2 Earnings Call Highlights
Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the
11h agoMarketChameleonBULLISH 67Product/PR
Annexon Extends Cash Runway Into 2028 as Key Clinical Milestones Approach for GBS and Vision Loss Therapies
August 12, 2026
Annexon's second quarter 2026 update reveals robust financial stability and approaching clinical milestones for its neuroinflammatory disease programs, with cash reserves and expanded credit facility supporting operations into 2028. Pivotal regulatory submissions and trial readouts for tanruprubart (GBS) and vonaprument (GA) headline the coming year.
12h agoInvestorsHubBEARISH 34Earnings
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
Annexon shares fall after a wider-than-expected Q2 loss as clinical spending rises, while key tanruprubart and vonaprument milestones remain on track.
Annexon Biosciences ( ($ANNX) ) has provided an announcement. On August 12, 2026, Annexon reported second-quarter 2026 results and a series of clinical and corporat...
13h agoSEC 8-KNEUTRAL 50General
Annexon, Inc. (ANNX) files 8-K
Filed: 2026-08-12 AccNo: 0001193125-26-345672 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
13h agoInvesting.com MarketsBEARISH 42General
Why is Annexon stock sliding today?
Why is Annexon stock sliding today?
13h agoSeeking AlphaBEARISH 34Earnings
Annexon Biosciences GAAP EPS of -$0.28 misses by $0.04
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4...
Frequently asked questions
Why is ANNX stock moving today?
ANNEXON INC (ANNX) is drawing unusual attention today. Our newswire has captured 11 stories on ANNX across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100). The most recent driver: "Annexon outlines Q4 BLA filing for tanruprubart while adding month 24 dual primary endpoint to ARCHER II" (Seeking Alpha).
Is ANNX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ANNX coverage reads 54/100 over 11 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →